Skip to main content


Featured Article
A Class II recall is active for a prescription medication used to treat patients with type 2 diabetes.
Researchers have found that older patients with diabetes do not find doctors’ medication recommendations to be intuitive and that clearer communication about medication rationale is needed.


Kiersten Combs, vice president of US Cardiovascular & Metabolic Disease, and Jim McDermott, vice president of US Medical Affairs and Metabolism, both at AstraZeneca, highlight how the use of Farxiga and other SGLT2 inhibitors impact payers and…
Julie Lauffenburger, PharmD, explains how more intensive insulin-adherence interventions impact patient outcomes and highlights the challenges faced when implementing these interventions.
Christina Nguyen, senior research analyst, and Mary Beth Landrum, PhD, professor of health care policy, both at Harvard Medical School, explain why inadequate risk adjustment could counterproductively reduce payments to groups whose patient…
Dr. Susan Cornell talks with Dr. Randolph Fugit about the importance of more pharmacists becoming certified diabetes instructors.

Interactive Features

Does hepatitis C treatment success improve insulin resistance in patients with diabetes?
Back to Top